There is a substantial interest in high quality, functional antibodies against membrane spanning proteins. Generating antibodies specific for these targets in their native conformation is very challenging, yet crucial for therapeutic and diagnostic antibody development.
The intrinsic advantage of in-solution, cell based assays over ELISA is that they facilitate the study of antibody-antigen interaction in their native environment: the cell surface. The iQue Screener scales up the throughput of such assays to several thousand samples/day, and it is a powerful tool to screen large antibody panels for properties beyond mere antigen binding.
This webinar will overview:
- How ModiQuest Research maximized their chances of finding therapeutic leads by implementing the iQue Screener platform.
- The use of the iQue Screener platform in various stages of antibody discovery campaigns, from stable target expressing cell line selection, to high throughput hybridoma screening, and finally to functional antibody lead characterization.
- The ability of the iQue Screener platform to simultaneously combine testing for control antigens, species cross reactivity and multiple antibody projects in a single primary screen.
- The key benefits of using no-wash, miniaturized, high throughput assay formats to screen large antibody libraries.
Andrea Gorlani, Ph.D., Scientist, ModiQuest Research
Andrea Gorlani obtained his PhD from Utrecht University, where he studied the properties of HIV-neutralizing antibodies and their development as microbicidal drug. He continued his research on mechanisms of viral evasion and on antibody effector functions as a postdoc at Utrecht University and University of California, Irvine. In 2015, he joined ModiQuest Research where he is responsible for the cell culture division. Together with his team, he introduced the ModiVacc™ technology, a novel live-cell immunization method to generate high affinity antibodies against poorly immunogenic membrane spanning proteins.
Thomas Duensing, Ph.D., Chief Technology Officer, IntelliCyt Corporation
Tom has more than 17 years of experience in scientific research, drug discovery and product development in the area of assay, applications and reagent systems. Tom was Senior Director of In Vitro Pharmacology at Tanox, where he built a successful assay development and high throughput screening program which contributed to the advancement of therapeutic monoclonal antibody candidates into clinical development. Prior to Tanox, Tom was Director of Assay Development at Cellomics and has also held research scientist positions at the National Institutes of Health’s Rocky Mountain Labs and Syntex.
Who Should Attend?
Research scientists from pharmaceutical and biotechnology companies, and academia working within cancer research, immunology, immuno-oncology, and immunotherapy, in application areas such as:
- Target identification/Validation
- Antibody Library Screening
- Lead optimization and characterization
- Protein/Antibody Engineering
IntelliCyt Corporation is the market leader in suspension-cell analysis platforms for immunology and immuno-oncology profiling, antibody discovery, and screening of immune targets in drug discovery and translational research. The iQue Screener platform is an integrated instrument, software and reagent system that enables rapid, high content, multiplexed analysis of cells and beads in suspension to gain a better understanding of normal and disease processes.This information is used to revolutionize the discovery and development of drugs and to provide new insight into disease. IntelliCyt product portfolio includes the iQue® Screener family of instruments, MultiCyt® cell-based and bead-based reagents and ForeCyt® Software for data analysis and visualization.